Residence structures and related methods

Patent metadata

Field	Value
Publication number	US-10517819-B2
Application number	US-201916277516-A
Country	US
Kind code	B2
Filing date	Feb 15, 2019
Priority date	Jun 11, 2014
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

Described are gastric residence structures that include an active substance. The gastric residence structures may include one or more arms that include a loadable polymeric component, an elastic polymeric component, and a separate linker component. The linker may connect the one or more arms with the elastic polymeric component. The gastric residence structures may be configured to be folded and physically constrained during administration and may be configured to assume an open retention shape upon removal of a constraint. The change between the folded shape and the open retention shape may be mediated by the elastic polymeric component that undergoes elastic deformation when the residence structure is in the folded shape and recoils when the gastric residence structure assumes the open retention shape.

First claim

What is claimed is:

1. A gastric residence structure comprising an active substance, the gastric residence structure comprising:
one or more arms comprising a loadable polymeric component, wherein the loadable polymeric component comprises the active substance, and the active substance is a therapeutic agent or a diagnostic agent;
an elastic polymeric component; and
a separate linker component, said linker connecting the one or more arms with the elastic polymeric component;
wherein the gastric residence structure is configured to be folded and physically constrained during administration and is configured to assume an open retention shape upon removal of a constraint, wherein change between the folded shape and the open retention shape is mediated by the elastic polymeric component that undergoes elastic deformation when the residence structure is in the folded shape and recoils when the gastric residence structure assumes the open retention shape; and
wherein the linker degrades, dissolves, disassociates, or mechanically weakens in a gastric environment which results in loss of retention shape integrity and passage out of a gastric cavity.

2. The gastric residence structure of claim 1 , comprising a plurality of active substances.

3. The gastric residence structure of claim 1 , wherein the gastric residence structure is configured to control a release rate of the active substance.

4. The gastric residence structure of claim 1 , wherein the active substance is entrapped within a polymer matrix of the loadable polymeric component.

5. The gastric residence structure of claim 1 , wherein the active substance is chemically bonded to a polymer of the loadable polymeric component.

6. The gastric residence structure of claim 1 , wherein the loadable polymeric component comprises polycaprolactone (PCL).

7. The gastric residence structure of claim 1 , wherein the loadable polymeric component comprises, poly(ethylene-co-vinyl acetate), or polyethylene glycol (PEG).

8. The gastric residence structure of claim 1 , wherein the loadable polymeric component comprises at least 10 wt % active substance of the total weight of the loadable polymeric component.

9. The gastric residence structure of claim 1 , wherein the loadable polymeric component comprises 10-50 wt % active substance of the total weight of the loadable polymeric component.

10. The gastric residence structure of claim 1 , wherein the gastric residence structure is configured such that the active substance is released from the loadable polymeric component at a particular initial average rate as determined over the first 24 hours of release, and wherein the active substance is released at an average rate of at least 1% of the initial average rate over a 24 hour period after the first 24 hours of release.

11. The gastric residence structure of claim 1 , wherein the active substance is a biological macromolecule, a vitamin, or a supplement.

12. The gastric residence structure of claim 1 , wherein the active substance is a nonsteroidal anti-inflammatory drug.

13. The gastric residence structure of claim 1 , wherein the active substance is a selective serotonin reuptake inhibitor, a blood thinning agent, a steroid, an antagonist, a cardiac glycoside, an alpha blocker, a cholesterol absorption inhibitor, a metabolite, an antihistamine, an opioid, a proton-pump inhibitor, an antiviral agent, an antibiotic, an anti-malarial agent, sulfonamides, a substance abuse treatment, a contraceptive, a stimulant, an analgesic, an anti-analgesic, an anti-inflammatory drug, an antipyretic, an antidepressant, an antiepileptic, an anti-proliferative, an anti-cancer agent, an antimigraine drug, an antimicrobial, an antifungal, an antiviral, an antiparasitic, an antimuscarinic, an anxioltyic, a bacteriostatic, a sedative, a hypnotic, a bronchodilator, an anti-asthma drug, a cardiovascular drug, an anesthetic, an anticoagulant, a dopaminergic, an electrolyte, a gastro-intestinal drug, a muscle relaxant, a parasympathomimetic, an anorectic, an anti-narcoleptic, a protein, a peptide, a hormone, a nucleic acid, a gene construct, an 3-hydroxy-3-methyl-glutaryl (HMG) co-A reductase inhibitor, a mineral, a prostaglandin, a nutritional supplement, a corticosteroid, a nutraceutical, a plant extract, or a phytohormone.

14. The gastric residence structure of claim 1 , wherein the active substance is meloxicam, escitalopram, clopidogrel, prasugrel, prednisone, naloxone, montelukast, digoxin, tamsulosin, ezetimibe, colchicine, loratadine, cetirizine, loperamide, omeprazole, entecavir, ciprofloxacin, azithromycin, quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfadoxine, sulfamethoxypyridazine, mefloquine, atovaquone, primaquine, halofantrine, clindamycin, artemisinin, artemisinin derivatives, artemether, dihydroartemisinin, arteether, artesunate, synthroid/levothyroxine, varenicline, caffeine, folic acid, calcium, iodine, iron, zinc, thiamine, niacin, vitamin C, or vitamin D.

15. The gastric residence structure of claim 1 , wherein the active substance is an a selective serotonin reuptake inhibitor, an antidepressant, an anxiolytic, a sedative, a hypnotic, an opioid, an antimigraine drug, a cholesterol absorption inhibitor, a substance abuse treatment, or an immunosuppressant agent.

16. The gastric residence structure of claim 1 wherein the active substance is an HMG co-A reductase inhibitor, a blood thinning agent, a cardiac glycoside, an alpha blocker, or a cholesterol absorption inhibitor.

17. The gastric residence structure of claim 1 wherein the active substance is prednisone.

18. The gastric residence structure of claim 1 , wherein the active substance is an antipsychotic.

19. The gastric residence structure of claim 18 , wherein the antipsychotic comprises risperidone.

20. The gastric residence structure of claim 1 , wherein the active substance is a neuroprotective agent.

21. The gastric residence structure of claim 1 , wherein the active substance is memantine.

22. The gastric residence structure of claim 1 , wherein the active substance is a substance abuse treatment.

23. The gastric residence structure of claim 22 , wherein the substance abuse treatment is methadone.

24. The gastric residence structure of claim 1 , wherein the active substance is a statin.

25. The gastric residence structure of claim 24 , wherein the statin is rosuvastatin.

26. The gastric residence structure of claim 1 , wherein the active substance is an immunosuppressant.

27. The gastric residence structure of claim 1 , wherein the active substance is an antibiotic.

28. The gastric residence structure of claim 27 , wherein the antibiotic is doxycycline.

29. The gastric residence structure of claim 1 , wherein the active substance is a cardiovascular drug.

30. The gastric residence structure of claim 1 , wherein the active substance is an analgesic.

31. The gastric residence structure of claim 1 , wherein the active substance is buprenorphine.

32. The gastric residence structure of claim 1 , wherein the active substance is loaded into the loadable polymeric component by a process comprising powder mixing, solvent loading, melt loading, or physical blending.

33. A method for delivering a residence structure, comprising: a

Assignees

• Massachusetts Inst Technology
• Brigham & Womens Hospital Inc

Inventors

• Bellinger Andrew
• Zhang Shiyi
• Traverso Carlo Giovanni
• Langer Robert S
• Mo Stacy
• Grant Tyler
• Jafari Mousa
• Glettig Dean Liang
• Diciccio Angela
• Wood Jr Lowell L
• Eckhoff Philip A

Classifications

• A61K47/6901

  Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• C08L2203/02

  for biomedical use · CPC title

• C08G18/4277

  Caprolactone and/or substituted caprolactone · CPC title

• C08G2230/00

  Compositions for preparing biodegradable polymers · CPC title